MedTrace Logo

Incidence and Predictors of Bleeding During and Following ERCP

NCT05929404 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5872

Last updated 2024-01-09

No results posted yet for this study

Summary

The incidence of bleeding during ERCP and following ERCP has been estimated using retrospective sources, but granular predictors of bleeding remain unknown, including the use of direct-acting anticoagulants and discontinuation and resumption patterns surrounding their use. In this study, we will aim to assess the incidence and predictors of intra-procedural bleeding during ERCP, and clinically significant post-procedural bleeding following ERCP.

Conditions

  • Bleeding UGI (During or Post-ERCP)

Sponsors & Collaborators

  • McGill University

    collaborator OTHER

  • University of Ottawa

    collaborator OTHER

  • Queen's University

    collaborator OTHER

  • Island Health, Victoria, BC

    collaborator OTHER

  • University of Toronto

    collaborator OTHER

  • Radboud University Medical Center

    collaborator OTHER

  • Halton Healthcare

    collaborator UNKNOWN

  • University of Calgary

    lead OTHER

Principal Investigators

  • Nauzer Forbes, MD MSc · Peter Lougheed Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2023-08-30
Completion
2023-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05929404 on ClinicalTrials.gov